Erica Hughes, MD
Pulmonary Disease · Burnet, TXNPI 1316080740
Payments from drug & device makers
Across 828 payments — averaging $55.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$31K
- GSK$4K
- Boehringer Ingelheim$4K
- Sanofi$851
- Regeneron Healthcare Solutions, Inc.$679
- Grifols USA, LLC$583
- plus $4K from 28 others
What the payments were for
- Consulting fees$2000%
- Speaking & faculty fees$28,08061%
- Travel & lodging$2,3205%
- Food & beverage$15,06733%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $31,236 |
| GSK | 351 | $4,444 |
| Boehringer Ingelheim | 93 | $4,092 |
| Sanofi | 41 | $851 |
| Regeneron Healthcare Solutions, Inc. | 29 | $679 |
| Grifols USA, LLC | 26 | $583 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $354 |
| United Therapeutics Corporation | 18 | $349 |
| Mylan Specialty L.p. | 20 | $337 |
| Insmed, Inc. | 13 | $328 |
| Amgen | 21 | $304 |
| Inspire Medical Systems, Inc. | 5 | $294 |
| Bayer | 1 | $200 |
| Electromed, Inc. | 13 | $180 |
| Medtronic | 1 | $177 |
| Globus Medical | 1 | $175 |
| Philips North America LLC | 11 | $167 |
| Teleflex LLC | 1 | $111 |
| Sunovion Pharmaceuticals Inc. | 7 | $101 |
| Jazz Pharmaceuticals Inc. | 5 | $99 |
| Merck | 4 | $87 |
| Verona Pharma, Inc. | 3 | $86 |
| Inogen, Inc. | 4 | $86 |
| Covis Pharma GmbH | 4 | $83 |
| Axsome Therapeutics, Inc. | 4 | $80 |
| Pulmonx Corporation | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 3 | $64 |
| Pfizer | 2 | $43 |
| Lilly USA, LLC | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Itamar Medical Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,796 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 70 | $1,005,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 944 | $776,143 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 602 | $456,083 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $160,518 |
| NucalaMepolizumab | 38 | $151,825 |
| Breo ElliptaFluticasone/Vilanterol | 261 | $124,108 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 185 | $122,984 |
| Fasenra PenBenralizumab | 19 | $114,362 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 138 | $90,061 |
| Dupixent PenDupilumab | 16 | $75,762 |
| Spiriva RespimatTiotropium Bromide | 82 | $59,864 |
| EliquisApixaban | 62 | $41,149 |
| SymbicortBudesonide/Formoterol Fumarate | 116 | $35,891 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 51 | $34,571 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 231 | $34,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $4,092 | $1,222,664388 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $4,444 | $1,171,6271,461 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $31,236 | $506,662749 claims |
| Grifols USA, LLCProlastin C | $583 | $160,51824 claims |
| PfizerEliquis | $43 | $41,14962 claims |
| MerckDulera | $87 | $29,30465 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Burnet
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.